Asymchem’s 2025 ESG Report: Carbon-Peak Pledge by 2030, MSCI ‘A’ Rating, S&P Global Industry Leader Status

Bulletin Express04-20

Asymchem Laboratories (Tianjin) Co., Ltd. (Asymchem, 06821) has released its fifth Environmental, Social and Governance (ESG) Report, outlining the CDMO’s 2025 sustainability performance, governance upgrades and medium-term decarbonisation roadmap.

• Governance Framework – The Board, supported by a Strategy Committee and a newly established Group-level EHS Office, supervises all ESG matters. Independent Directors account for one-third of the nine-member board, while women hold 44.44 % of seats.

• ESG Ratings – In 2025 the company was rated “A” by MSCI, “AA” by WIND and received a 70-point score in S&P Global’s CSA, earning “Industry Leader” status in the S&P Sustainability Yearbook 2026. It also obtained a CDP Climate Change score of “B” and an EcoVadis Silver medal.

• Climate Targets – Asymchem commits to peak carbon emissions by 2030 and achieve net-zero by 2060. Small-molecule sites aim to cut Scope 1 and 2 emissions by 10 % from a 2022 baseline by 2030; Jilin Asymchem and Asymchem Pharmaceuticals target 42 % Scope 1&2 and 25 % Scope 3 reductions by 2030 (targets validated by SBTi).

• Emissions & Energy – 2025 location-based Scope 1+2 emissions reached 273,519.75 tCO₂e. Renewable power covered 22.19 % of electricity use, while clean-energy sources accounted for 30.58 % of total energy consumption. Two plants secured ISO 50001 certification.

• Environmental Compliance – No environmental fines, penalties or major incidents were recorded. Wastewater COD discharge stood at 167.55 t; VOC emissions at 36.13 t. Hazardous-waste landfill was eliminated for production-generated waste.

• Workforce & Safety – Headcount rose to 10,617 (32.11 % women); average training hours reached 97.78 per employee with 100 % coverage. Lost-time injury frequency fell to 0.59 per million hours and no occupational disease cases occurred.

• Innovation & IP – R&D expenditure totalled RMB 593.26 million (8.89 % of revenue). The company held 577 patents, applied for 37 new patents and registered eight software copyrights during the year.

• Financial Snapshot – 2025 revenue was RMB 6.67 billion with net profit attributable to shareholders of RMB 1.13 billion.

• Community & Supply Chain – ESG clauses cover 100 % of suppliers; 1,509 key suppliers took part in capacity-building programmes. Charitable spending reached RMB 11.39 million, with rural-revitalisation funds of RMB 4.30 million directed to infrastructure and medical aid projects.

Asymchem states that it will continue to expand green chemistry, renewable-energy adoption and digitalised safety management to meet its 2030 and 2060 climate goals while supporting global pharmaceutical customers with low-carbon CDMO solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment